- How much did the merger cost Globus? Under the terms of the all-stock deal, NuVasive shareholders will receive 0.75% of a Globus share for each of their NuVasive holdings. That values each share of NuVasive stock at about $57.72 and adds up to a total equity value of $3.1 billion for the merger.
- How is it going to be done? Each share of Nuvasive will convert into 0.75 of one of Globus. There are 51.9 million shares of Nuvasive. It means that Globus has to issue 38.925 million new shares for Nuvasive shareholders (51.9 million * 0.75). Before the fusion, Globus Medical accounted for 103 million shares. Now, after, it has 141.925 million that generates a share dissolution. Globus shareholders consider that their property in the new company has been reduced.
- Globus bought Nuvasive without cash, but did they pay more than it was worth? NuVasive market capitalization on Friday, February 10th, was $2.320 billion. On that same closing date, the Globus share was worth $60, so the value of the new 38.924 million new shares was $2.335 billion. So it seems they have paid in this deal what it’s worth.
About Globus Medical
Globus Medical is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.
About NuVasive
NuVasive is a leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The company’s less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.